Autologous Cell Therapy Product Market Anticipated to Reach Valuation of USD 34.8 Billion by 2028

In terms of revenue, the Global Autologous Cell Therapy Product Market is expected to reach USD 34.8 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 16.90% from 2022 to 2028. The rising incidence of chronic conditions such as autoimmune diseases, blood disorders, cancer, and others has given the rise in the population suffering from incurable diseases are major factors attributing to the growth of the autologous cell therapy business are factors for the growth of the market.

Key Findings:

• The bone marrow source segment contributed maximum share in Autologous Cell Therapy Product Market in 2021. Since most of the hematopoietic stem cells and mesenchyme are recovered from the bone marrow and bone marrow is the center for most of the stem cells. The widespread Research and Development (R&D) activities for bone marrow-derived stem cells is expected to boost market growth.
• Research center End-User segment accounted potential growth for Autologous Cell Therapy Product Market in 2021. There are several donations and investments done to the research facilities by the public sectors & private sectors that are encouraging the segmental growth of Autologous Cell Therapy Product Market.
• North America held the maximum share for Autologous Cell Therapy Product Market in 2021. This surge is majorly accounted for owing to the strong economic growth, access to the latest advanced technologies, and substantial investment by the private & public sectors.

Some of key players in Autologous Cell Therapy Product Market include - Vericel Corporation (US), Pharmicell Co. Inc(South Korea), Holostem Terapie Avanzate S.R.L (Italy), Lineage Cell Therapeutics Inc. (US), Opexa Therapeutics (US).

The low risk of complications associated with autologous treatment is anticipated to propel the growth of Autologous Cell Therapy Product Market in the coming years. Affordability, no need for identification of an HLA-matched donor, the improved survival rate of patients, reduce risk of graft-versus-host diseases are some other factors that bolster the growth of Autologous Cell Therapy Product Market in present years. In addition, this therapy is used for transforming medicinal treatments by developing several new therapies. Its application is vast and promising in the coming years. The therapy is considered to be a safer and more effective technology in comparison with the existing transplant technologies, such as allogeneic and xenotransplants. Autologous transplants facilitate in reduction of risks associated with disease transmission, immunological reactions, and bio-incompatibility. All these parameters are also expected to witness the maximum growth of Autologous Cell Therapy Product Market over the projected time period.

Asia Pacific accounted to mention fastest-growing region for Autologous Cell Therapy Product Market during the forecast period, owing to the factors such as easy approval for clinical trials, increase in Research and Development (R&D) initiatives to develop therapeutic options for chronic diseases, and availability of state-of-the-art research infrastructure in this region. The United States is a major contributor to key market vendors and research companies located in the country. The region has several pipeline projects that are fostering market demand. All these reasons are also responsible for bolstering the growth of Autologous Cell Therapy Product Market in this region.